213 related articles for article (PubMed ID: 7562544)
1. Development of behavioral sensitization to cocaine: influence of kappa opioid receptor agonists.
Heidbreder CA; Babovic-Vuksanovic D; Shoaib M; Shippenberg TS
J Pharmacol Exp Ther; 1995 Oct; 275(1):150-63. PubMed ID: 7562544
[TBL] [Abstract][Full Text] [Related]
2. kappa-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine.
Shippenberg TS; LeFevour A; Heidbreder C
J Pharmacol Exp Ther; 1996 Feb; 276(2):545-54. PubMed ID: 8632320
[TBL] [Abstract][Full Text] [Related]
3. Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist.
Heidbreder CA; Schenk S; Partridge B; Shippenberg TS
Synapse; 1998 Nov; 30(3):255-62. PubMed ID: 9776129
[TBL] [Abstract][Full Text] [Related]
4. The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat.
Heidbreder CA; Goldberg SR; Shippenberg TS
Brain Res; 1993 Jul; 616(1-2):335-8. PubMed ID: 8395306
[TBL] [Abstract][Full Text] [Related]
5. Dissociable effects of the kappa-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine.
Vanderschuren LJ; Schoffelmeer AN; Wardeh G; De Vries TJ
Psychopharmacology (Berl); 2000 May; 150(1):35-44. PubMed ID: 10867974
[TBL] [Abstract][Full Text] [Related]
6. Kappa-opioid receptor modulation of nicotine-induced behaviour.
Hahn B; Stolerman IP; Shoaib M
Neuropharmacology; 2000 Oct; 39(13):2848-55. PubMed ID: 11044755
[TBL] [Abstract][Full Text] [Related]
7. Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity.
Collins SL; Gerdes RM; D'Addario C; Izenwasser S
Behav Pharmacol; 2001 Jul; 12(4):237-45. PubMed ID: 11548109
[TBL] [Abstract][Full Text] [Related]
8. Pertussis and cholera toxins modulate kappa-opioid receptor agonists-induced hypothermia and gut inhibition.
Shukla VK; Turndorf H; Bansinath M
Eur J Pharmacol; 1995 Mar; 292(3-4):293-9. PubMed ID: 7796869
[TBL] [Abstract][Full Text] [Related]
9. Kappa-opioid receptor activation prevents alterations in mesocortical dopamine neurotransmission that occur during abstinence from cocaine.
Chefer VI; Morón JA; Hope B; Rea W; Shippenberg TS
Neuroscience; 2000; 101(3):619-27. PubMed ID: 11113311
[TBL] [Abstract][Full Text] [Related]
10. Effects of kappa-opioid receptor agonists on long-term cocaine use and dopamine neurotransmission.
Collins SL; D'Addario C; Izenwasser S
Eur J Pharmacol; 2001 Aug; 426(1-2):25-34. PubMed ID: 11525767
[TBL] [Abstract][Full Text] [Related]
11. Prolonged antagonism of morphine-induced locomotor stimulation by kappa opioid agonists: enhancement by prior morphine exposure.
Pearl SM; Glick SD
Neurosci Lett; 1996 Jul; 213(1):5-8. PubMed ID: 8844699
[TBL] [Abstract][Full Text] [Related]
12. Sensitization to the conditioned rewarding effects of morphine and cocaine: differential effects of the kappa-opioid receptor agonist U69593.
Shippenberg TS; LeFevour A; Thompson AC
Eur J Pharmacol; 1998 Mar; 345(1):27-34. PubMed ID: 9593590
[TBL] [Abstract][Full Text] [Related]
13. Depletion of serotonin decreases the effects of the kappa-opioid receptor agonist U-69593 on cocaine-stimulated activity.
Zakharova E; Collins SL; Aberg M; Kumar A; Fernandez JB; Izenwasser S
Eur J Pharmacol; 2008 May; 586(1-3):123-9. PubMed ID: 18395712
[TBL] [Abstract][Full Text] [Related]
14. Central kappa opioid receptor-evoked changes in renal function in conscious rats: participation of renal nerves.
Kapusta DR; Obih JC
J Pharmacol Exp Ther; 1993 Oct; 267(1):197-204. PubMed ID: 8229746
[TBL] [Abstract][Full Text] [Related]
15. Indirect dopamine agonists augment the locomotor activating effects of the kappa-opioid receptor agonist U-50,488 in preweanling rats.
McDougall SA; Rodarte-Freeman AL; Nazarian A
Dev Psychobiol; 1999 Apr; 34(3):183-93. PubMed ID: 10204094
[TBL] [Abstract][Full Text] [Related]
16. Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593.
Acri JB; Thompson AC; Shippenberg T
Synapse; 2001 Mar; 39(4):343-50. PubMed ID: 11169785
[TBL] [Abstract][Full Text] [Related]
17. Central kappa opioids blunt the renal excretory responses to volume expansion by a renal nerve-dependent mechanism.
Kapusta DR; Obih JC
J Pharmacol Exp Ther; 1995 Apr; 273(1):199-205. PubMed ID: 7714767
[TBL] [Abstract][Full Text] [Related]
18. Effects of the kappa-opioid receptor agonist, U69593, on the development of sensitization and on the maintenance of cocaine self-administration.
Schenk S; Partridge B; Shippenberg TS
Neuropsychopharmacology; 2001 Apr; 24(4):441-50. PubMed ID: 11182539
[TBL] [Abstract][Full Text] [Related]
19. kappa-Opioid receptors in the substantia nigra pars reticulata mediate the U-50,488-induced locomotor activity of preweanling rats.
Collins RL; Zavala AR; Nazarian A; McDougall SA
Brain Res Dev Brain Res; 2000 Jan; 119(1):97-103. PubMed ID: 10648876
[TBL] [Abstract][Full Text] [Related]
20. The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity.
Crawford CA; McDougall SA; Bolanos CA; Hall S; Berger SP
Psychopharmacology (Berl); 1995 Aug; 120(4):392-9. PubMed ID: 8539319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
